As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
ApexOnco Front Page
Recent articles
Summit and Nuvalent have scored prized plenary spots.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Some big deals in the second quarter have raised hopes that takeouts are back.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Adverse events will be closely watched when full data are reported.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
